Denali Therapeutics Inc. filings document regulatory, financial and governance disclosures for a biotechnology company developing blood-brain-barrier-crossing therapeutics. Recent 8-K reports record operating results, FDA approval and launch-related disclosures for AVLAYAH™, clinical pipeline updates, and material events tied to collaboration agreements and royalty funding arrangements.
Denali’s proxy materials cover board matters, executive compensation, equity awards and shareholder voting items. Its event filings also describe capital-structure and financing obligations, Regulation FD disclosures, exhibit-based press releases, and formal updates on TransportVehicle-enabled programs across lysosomal storage and neurodegenerative disease indications.
Denali Therapeutics Inc. (DNLI) reported that Chief Medical Officer Peter Scott Chin sold 1,654 shares of common stock on September 4, 2026 at a weighted average price of $22.29 per share. The shares were sold to satisfy tax obligations related to settlement of previously vested restricted stock units, and he now holds 204,538 shares, including 142,845 unvested RSUs and 1,790 shares acquired under the ESPP on June 1, 2026. No Rule 10b5-1 trading plan is reported for this transaction.
Denali Therapeutics Inc. (DNLI) is the subject of a Form 144 notice filed for the potential sale of 1,654 shares of its common stock by stockholder Chin Peter Scott through Morgan Stanley Smith Barney LLC. The shares relate to vested Restricted Stock Units, and the filer notes that shares are being sold to cover a tax obligation from the settlement of those awards.
Denali Therapeutics Inc. (DNLI) reported that director Nancy Thornberry sold common stock in two open-market or private transactions on September 2, 2026. She sold 10,824 shares at a weighted average price of $22.85 per share and 615 shares at a weighted average price of $23.74 per share. The filing states these sales were effected under a Rule 10b5-1 trading plan adopted June 3, 2026 and that her holdings include 6,408 unvested RSUs after the reported transactions.
Denali Therapeutics Inc. (DNLI) reported that its COFO and Secretary, Alexander O. Schuth, sold 2,768 shares of Common Stock on September 1, 2026 at $23.44 per share in an open-market or private transaction. The sale was made pursuant to a Rule 10b5-1 trading plan adopted March 27, 2026. After this transaction, Schuth directly held 278,995 shares, including 135,475 unvested RSUs, and indirectly held 523,749 shares through The Schuth Family Trust, for which he serves as trustee.
Denali Therapeutics Inc. (DNLI) director Nancy Thornberry filed a notice of proposed sale under Rule 144 for 11,439 shares of common stock, with an indicated aggregate value of $266,128.34, to be sold through Morgan Stanley Smith Barney LLC on NASDAQ.
The shares were acquired from the issuer upon vesting of restricted stock units during the period from January 8, 2024 through May 31, 2025.
Denali Therapeutics Inc. (DNLI) is the issuer for a planned sale of common stock reported under Rule 144 on behalf of officer Alexander Schuth. The notice covers 2,768 shares of common stock to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services, with an approximate aggregate market value of $65,767.68 as referenced. The shares relate to Restricted Stock Units with an acquisition date of 08/09/2026, and the proposed sale date is 09/01/2026 on NASDAQ.
Denali Therapeutics Inc. President and CEO Ryan J. Watts reported a bona fide gift of 32,220 shares of Denali common stock on August 12, 2026. The in-kind charitable contribution was made to a donor advised fund from shares held indirectly through the Watts Family 2015 Trust, for which he serves as trustee. After the transactions, he reports 2,120,384 indirect shares and 296,833 direct shares, including 184,915 unvested RSUs.
Denali Therapeutics Inc. officer Alexander O. Schuth reported selling 2,857 shares of common stock on 2026-08-11 at $25.07 per share, with a footnote stating the shares were sold to satisfy tax obligations related to previously vested RSUs. Following this transaction, he directly holds 281,763 shares, including 135,475 unvested RSUs and 1,792 shares acquired under the ESPP on June 1, 2026, and indirectly holds 523,749 shares through The Schuth Family Trust, where he serves as trustee. The filing indicates the transaction was not made under a Rule 10b5-1 trading plan.
A holder of Denali Therapeutics Inc. common stock submitted a notice to sell 2,857 shares through Morgan Stanley Smith Barney LLC Executive Financial Services on the NASDAQ market. The shares relate to a restricted stock lapse dated 08/10/2026 and are tied to equity compensation, with an indicated aggregate value of $71,623.51 as of 08/11/2026.
Denali Therapeutics reported Q2 2026 results as it transitioned to commercialization. Net product revenue from AVLAYAH, its first approved therapy for Hunter syndrome, was $3.6 million for both the quarter and first half, following FDA accelerated approval in March and U.S. launch in April.
Net loss was $127.6 million for the quarter and $256.0 million for the first six months of 2026. Research and development expense fell to $97.0 million in the quarter and $200.9 million year to date, down 6% and 8% versus 2025, while selling, general and administrative expense rose with commercialization efforts. Cash and cash equivalents were $201.5 million at June 30, 2026, with short- and long-term marketable securities of $508.9 million and $229.5 million, respectively.
Denali strengthened its balance sheet through a $200.0 million synthetic royalty funding with Royalty Pharma tied to a 9.25% revenue participation right on AVLAYAH and, subsequent to quarter end, a $195.0 million sale of a Rare Pediatric Disease Priority Review Voucher. Pipeline updates included Takeda’s termination of the DNL593 collaboration, with full rights reverting to Denali, and discontinuation of Biogen-partnered BIIB122/DNL151 development in idiopathic Parkinson’s disease after the Phase 2b LUMA study did not meet its endpoints.